Clinical features, treatments, and outcomes of atezolizumab-induced diabetes mellitus in cancer patients [0.03%]
阿特珠单抗致糖尿病的临床特征、治疗及转归-1例报告
Jian Xiao,Zhi Xia,Zhu Wu et al.
Jian Xiao et al.
To explore the clinical characteristics of diabetes mellitus (DM) induced by atezolizumab in cancer patients and provide evidence to guide the rational clinical application of atezolizumab. We conducted a retrospective study on diabetes ind...
Characterizing pulmonary adverse events associated with the immune checkpoint inhibitor avelumab: a FAERS-based pharmacovigilance study from 2013 to 2024 [0.03%]
基于FAERS的药物警戒研究（2013-2024）：与免疫检查点抑制剂阿维鲁单抗相关的肺部不良事件特征分析
Connor Frey
Connor Frey
The rise of immunotherapies, particularly PD-L1 inhibitors like avelumab, has advanced cancer care, but its pulmonary safety profile remains unclear. Using FAERS data from 2013-2023, we evaluated respiratory complications linked to avelumab...
DNMT1 reduces cisplatin sensitivity partially through downregulating FOXO3a in ovarian cancer cells [0.03%]
DNA甲基转移酶1通过降低FOXO3a蛋白表达部分介导卵巢癌细胞对顺铂耐药性
Chong Guo,Qingqing Yu,Fangzhou Li et al.
Chong Guo et al.
Most individuals with ovarian cancer (OC) develop cisplatin resistance while undergoing treatment. Bioinformatic analysis has linked DNA Methyltransferase 1 (DNMT1) to chemoresistance development as well as FOXO3a expression in OC patients....
Palbociclib in liposarcoma: real-world multicenter data from the Turkish Oncology Group (TOG) [0.03%]
帕博西尼治疗脂肪肉瘤的疗效和安全性——来自土耳其肿瘤协会（TOG）的真实世界多中心数据
Fatih Kus,Hasan Cagri Yildirim,Dogan Bayram et al.
Fatih Kus et al.
Background: Well-differentiated (WDLPS) and dedifferentiated liposarcomas (DDLPS) are subtypes with distinct behaviors, often driven by CDK4 amplification. While CDK4/6 inhibitors such as palbociclib show promise in trial...
Combination therapy does not decrease 30-day mortality but increases antibiotic consumption in methicillin-sensitive S. aureus bacteraemia [0.03%]
联合疗法不会降低金黄色葡萄球菌败血症30天的死亡率，但会增加抗生素的使用量
Özge Özgen-Top,Pınar Aysert-Yildiz,Hamid Habibi et al.
Özge Özgen-Top et al.
Purpose: The study aimed to compare the impact of combination and monotherapy on mortality, antibiotic consumption using 'Days of Therapy (DOT)', and antibiotic-related adverse events in patients with methicillin-suscepti...
A Phase 1 study of abemaciclib plus abiraterone in Japanese patients with metastatic castration-resistant prostate cancer [0.03%]
阿贝西利联合阿比特龙治疗日本转移性去势抵抗性前列腺癌患者I期研究
Nobuaki Matsubara,Koji Dozono,Karim Nacerddine et al.
Nobuaki Matsubara et al.
The aim of this Phase 1, multicentre, open-label study was to evaluate the safety, tolerability and pharmacokinetics (PK) of abemaciclib administered at global recommended Phase 2 dose (RP2D) of 200 mg twice daily, combined with standard do...
Influencing factors of acute severe to very severe peripheral neuropathy induced by albumin-bound paclitaxel [0.03%]
影响白蛋白结合型紫杉醇所致急性重度外周神经病变的因素分析
Yi Huang,Lijuan Feng,Jing Hu et al.
Yi Huang et al.
Paclitaxel is the primary chemotherapy agents for many high-incidence cancers, and they also pose a significant risk for peripheral neuropathy. This study investigated the factors influencing paclitaxel-induced peripheral neuropathy (PIPN)....
Bacteriophage therapy in clinical practice: case studies of Pseudomonas aeruginosa infections [0.03%]
噬菌体疗法的临床实践：绿脓杆菌感染病例研究
Ahmed Elfadadny,Rokaia F Ragab,Osama Aldesoky Abd Alaziz et al.
Ahmed Elfadadny et al.
The increasing prevalence of multidrug-resistant (MDR) Pseudomonas aeruginosa infections poses a major challenge in clinical settings, particularly when antibiotic therapy fails and surgical source control is not feasible. Bacteriophage the...
Eribulin in metastatic breast cancer in the real-world - the way forward in the Indian setting [0.03%]
依拉立滨治疗转移性乳腺癌的真实世界研究——印度的未来之路
Dinesh Chandra Doval,Rupal Tripathi,Shweta Jain et al.
Dinesh Chandra Doval et al.
In a real-world setting, this study evaluated clinical parameters and outcomes with the administration of eribulin in heavily pre-treated Indian metastatic breast cancer (MBC) patients using electronic medical records. Among 145 patients, 4...
Striking effectiveness of siltuximab-based treatment in refractory idiopathic multicentric Castleman disease resembling IgG4-related disease [0.03%]
西利珠单抗治疗难治性多中心型Castleman病的疗效类似IgG4相关性疾病
Xing Gong,Weiwei Yan,Feng Zhang et al.
Xing Gong et al.
Castleman disease (CD) and immunoglobulin G4-related disease (IgG4-RD) are rare systemic immune-mediated disorders that share similar clinical manifestations and overlapping pathological features. We present a case of insidious idiopathic m...